Ping Xie

Research Assistant Professor

Northwestern University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Year:

2026

Approximately 20% of diffuse large B-cell lymphoma have aberrations involving the programmed death ligands 1 and 2 (PD-L1/PD-L2) locus. This justifies the investigation of PD-1 checkpoint inhibitors in the frontline therapy setting in a bid to improve outcomes, especially in patients with high-risk disease (antecedent low-grade lymphoma, MYC aberrancy, advanced staged disease, and intermediate/high-risk International Prognostic Index score). This phase 1b study evaluated the safety and preliminary efficacy of a combination of nivolumab and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) using a priming approach. Upon establishing the maximum tolerated dose of nivolumab, treatment consisted of a lead-in phase with nivolumab 240 mg × 1 followed 2 weeks later by combination nivolumab–R-CHOP given every 3 weeks for 6 cycles. A total of 33 patients were enrolled, of which 25 and 22 patients were evaluable for toxicity and efficacy, respectively. Estimated 18-month overall survival and progression-free survival rates were 95.4% and 72.7%, respectively. The observed therapy-related adverse events were not significantly different from previous reports on nivolumab and R-CHOP, respectively. Patient-reported outcomes did not suggest that the addition of nivolumab to R-CHOP led to worse quality of life measures. Exploratory analysis of biologic correlates showed an exhausted T-cell immunophenotype to be a predictor of progression and immunotoxicity, while also suggesting the effectiveness of a priming approach. This trial was registered at www.clinicaltrials.gov as #NCT03704714.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Despite the rapid utilization of immunotherapy, emerging challenges to the current immune checkpoint blockade need to be resolved. Here, we report that elevation of CD73 levels due to its aberrant turnover is correlated with poor prognosis in immune-cold triple-negative breast cancers (TNBCs). We have identified TRIM21 as an E3 ligase that governs CD73 destruction. Disruption of TRIM21 stabilizes CD73 that in turn enhances CD73-catalyzed production of adenosine, resulting in the suppression of CD8 + T cell function. Replacement of lysine 133, 208, 262, and 321 residues by arginine on CD73 attenuated CD73 ubiquitylation and degradation. Diminishing of CD73 ubiquitylation remarkably promotes tumor growth and impedes antitumor immunity. In addition, a TRIM21 high /CD73 low signature in a subgroup of human breast malignancies was associated with a favorable immune profile. Collectively, our findings uncover a mechanism that governs CD73 proteolysis and point to a new therapeutic strategy by modulating CD73 ubiquitylation.

Year:

2023

Collaborators (9)

Deyu Fang

Hosmer Allen Johnson Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Ishan Roy

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Weiguo Cui

Northwestern University

UNITED STATES
View details

Xinxin Song

University of Texas Southwestern Medical Center

UNITED STATES
View details

Shuo Ma

Professor of Medicine

Northwestern University

UNITED STATES
View details

Yueming Zhu

Assistant Professor

Emory University

UNITED STATES
View details

Yong Wan

Professor

Emory University School of Medicine

UNITED STATES
View details

Derek Wainwright

Associate Professor, Scientific Director for Brain Tumor Research

Loyola University Chicago Stritch School of Medicine

UNITED STATES
View details

Jennifer Wu

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details